Evidence map›Paper›PMID 36831968›Full record

ReviewBiosensors2023

Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application.

Akash Kumaran, Nathan Jude Serpes, Tisha Gupta, Abija James, Avinash Sharma, Deepak Kumar, Rupak Nagraik, Vaneet Kumar, Sadanand Pandey

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Current biosensing strategies based on in vitro T7 RNA polymerase reaction.Biotechnology notes (Amsterdam, Netherlands) · 2025
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akash KumaranFaculty of Applied Sciences and Biotechnology, Shoolini University, Solan 173229, Himachal Pradesh, India.
Nathan Jude SerpesFaculty of Applied Sciences and Biotechnology, Shoolini University, Solan 173229, Himachal Pradesh, India.
Tisha GuptaFaculty of Applied Sciences and Biotechnology, Shoolini University, Solan 173229, Himachal Pradesh, India.
Abija JamesFaculty of Applied Sciences and Biotechnology, Shoolini University, Solan 173229, Himachal Pradesh, India.ORCID 0000-0002-3119-3103
Avinash SharmaFaculty of Applied Sciences and Biotechnology, Shoolini University, Solan 173229, Himachal Pradesh, India.
Deepak KumarDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan 173229, Himachal Pradesh, India.ORCID 0000-0003-2241-0054
Rupak NagraikFaculty of Applied Sciences and Biotechnology, Shoolini University, Solan 173229, Himachal Pradesh, India.
Vaneet KumarDepartment of Natural Science, CT University, Ludhiana 142024, Punjab, India.
Sadanand PandeyDepartment of Chemistry, College of Natural Sciences, Yeungnam University, Gyeongsan 38541, Gyeongbuk, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the move of molecular tests from diagnostic labs to on-site testing becoming more common, there is a sudden rise in demand for nucleic acid-based diagnostic tools that are selective, sensitive, flexible to terrain changes, and cost-effective to assist in point-of-care systems for large-scale screening and to be used in remote locations in cases of outbreaks and pandemics. CRISPR-based biosensors comprise a promising new approach to nucleic acid detection, which uses Cas effector proteins (Cas9, Cas12, and Cas13) as extremely specialized identification components that may be used in conjunction with a variety of readout approaches (such as fluorescence, colorimetry, potentiometry, lateral flow assay, etc.) for onsite analysis. In this review, we cover some technical aspects of integrating the CRISPR Cas system with traditional biosensing readout methods and amplification technologies such as polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and recombinase polymerase amplification (RPA) and continue to elaborate on the prospects of the developed biosensor in the detection of some major viral and bacterial diseases. Within the scope of this article, we also discuss the recent COVID pandemic and the numerous CRISPR biosensors that have undergone development since its advent. Finally, we discuss some challenges and future prospects of CRISPR Cas systems in point-of-care testing.

Indexed as

Biosensing TechniquesCOVID-19Nucleic AcidsBiological AssayCOVID-19 TestingHumansNucleic Acid Amplification TechniquesPoint-of-Care SystemsPoint-of-Care TestingNucleic AcidsbiosensorCas effector proteinsCRISPRdiseasesE-CRISPR

Identifiers

PMID36831968
PMCPMC9953454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.